Nilutamide
From Wikipedia, the free encyclopedia
Nilutamide
|
|
Systematic (IUPAC) name | |
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl] imidazolidine-2,4-dione |
|
Identifiers | |
CAS number | 63612-50-0 |
ATC code | L02BB02 |
PubChem | 4493 |
DrugBank | APRD00150 |
Chemical data | |
Formula | C12H10N3F3O4 |
Mol. weight | 317.221 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | 38.0 to 59.1 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Nilutamide is an antiandrogen medication used in the treatment of advanced stage prostate cancer. Nilutamide blocks the androgen receptor, preventing its interaction with testosterone. This leads to a decrease in dihydrotestosterone (DHT) production. Because most prostate cancer cells rely on DHT for growth and spread, nilutamide can prolong life in men with prostate cancer. Nilutamide is marketed under the name Nilandron in the United States.
[edit] References
- Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J. Urol. 2003 May;169(5):1742-4. PMID 12686822